Poland· PL-100002059
ABE
A medicinal product containing acidum lacticum + acidum salicylicum, registered in Poland by Grupa Inco S.A..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Acidum lacticum + Acidum salicylicum
- Manufacturer
- Grupa Inco S.A.
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909990040919
- gtin05909990625796
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Acidum lacticum + acidum salicylicum in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/08346bf5-b629-4f47-a008-e0911429a99e GET /v1/drugs/08346bf5-b629-4f47-a008-e0911429a99e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Płyn na skórę",
"source": "urpl",
"strength": "(89 mg + 89 mg)/g",
"packaging": "05909990040919 ¦ OTC ¦ 354\n1 op. 8 g\n05909990625796 ¦ OTC ¦ Skasowane ¦ 47363\n30 op. 8 g",
"substance": "Acidum lacticum 89 mg/g + Acidum salicylicum 89 mg/g",
"common_name": "Acidum lacticum + Acidum salicylicum",
"pl_product_id": "100002059",
"pozwolenie_nr": "00409",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about acidum lacticum + acidum salicylicum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.